AbbVie sweeps back-to-back PhIIIs for uterine fibroid patients, adding to elagolix's blockbuster rep
AbbVie is on a roll.
The pharma giant $ABBV has rolled up its second and final positive Phase III for elagolix, one of its top …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
